OakChart

Artiva Biotherapeutics Inc

ARTVHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 11:15 AM ET

4.10+0.04 (1.02%)
2026-11-11 17:15 CET
Market cap
198.49 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-98.11 USD m
Free cash flow, TTM
-86.60 USD m
EPS diluted, TTM
-3.00
P/E
-
Compare

Price

ARTV against its 20, 50 and 200-day averages
2050200beat
4.006.008.0010.0012.004.3M8.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARTVclose 4.1020-day 4.9850-day 6.95200-day 8.004.10

71.8% under the 52-week high of 14.53 on 20 Apr 2026. 52-week low 2.96 on 9 Dec 2025. Last 15 sessions, 66.3% high to low

Profile

ARTV
52-week range, 10% of the way up
2.9614.53

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

IndexRUT
Employees104
IPOJul 19, 2024
Beta2.68
ATR, 14d0.32
Rel volume0.80
Short float16.58%
Insider own63.55%
Inst own71.57%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap202.76M
Enterprise Value-107.17M
Income-98.11M
Sales0.00M
Book/sh6.51
Cash/sh6.46
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees104
IPOJul 19, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.63
P/C0.64
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio19.88
Current Ratio19.88
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.00
EPS next Y-1.55
EPS next Q-0.55
EPS this Y20.12%
EPS next Y43.37%
EPS next 5Y24.88%
EPS past 3/5Y-12.33% -27.38%
Sales past 3/5Y- -
EPS Y/Y TTM7.78%
Sales Y/Y TTM-100.00%
EPS Q/Q35.99%
Sales Q/Q-
EarningsAug 06 AMC
EPS/Sales Surpr.-0.78% -

Ownership

Insider Own63.55%
Insider Trans45.49%
Inst Own71.57%
Inst Trans40.64%
ROA-39.90%
ROE-43.61%
ROIC-30.04%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-17.64%
SMA50-40.95%
SMA200-48.76%
Trades-

Technical

Shs Outstand49.27M
Shs Float17.82M
Short Float16.58%
Short Ratio4.36
Short Interest2.95M
52W High14.53 -71.77%
52W Low2.96 38.57%
Volatility3.29% 5.24%
ATR (14)0.32
RSI (14)23.17
Beta2.68
Rel Volume0.80
Avg Volume677.93K
Volume165,275

Performance

Perf Week-2.81%
Perf Month-34.79%
Perf Quarter-63.70%
Perf Half Y-60.94%
Perf YTD-4.39%
Perf Year14.25%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom2.33
Target Price20.75
Prev Close4.06
Price4.10
Change %1.02%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Oct 29, 2026DowngradeJJefferiesBuy → Hold$4-2.5%
Oct 27, 2026DowngradeWWedbushOutperform → Neutral$4-2.5%
Oct 27, 2026DowngradeNNeedhamBuy → Hold
Jun 11, 2025ResumedHH.C. WainwrightBuy$12+192.6%
Dec 30, 2024InitiatedHH.C. WainwrightBuy$20+387.6%
Aug 13, 2024InitiatedWWedbushOutperform$18+338.9%
Aug 13, 2024InitiatedTTD CowenBuy
Aug 13, 2024InitiatedNNeedhamBuy$23+460.8%
Aug 13, 2024InitiatedJJefferiesBuy$21+412.0%
Aug 13, 2024InitiatedCCantor FitzgeraldOverweight$23+460.8%

Peers

Mkt cap
TickerCompanyMkt cap
NKTXNkarta Inc96.44M
FATEFate Therapeutics Inc204.85M
CABACabaletta Bio Inc305.24M
KYTXKyverna Therapeutics Inc321.89M
ALLOAllogene Therapeutics Inc312.51M
IPSCCentury Therapeutics Inc311.56M
RNACCartesian Therapeutics Inc213.13M
SANASana Biotechnology Inc714.63M
CRBUCaribou Biosciences Inc40.54M
CLLSCellectis ADR103.43M

Insider trading

latest 14 of 57
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Horan ChristopherChief Tech Operations OfficerNov 02 '26Sale4.1810,42343,580302,321Nov 03 04:05 PM
Bush JenniferCOO, CLO, Compliance OfficerNov 02 '26Sale4.188,43935,284357,720Nov 03 04:05 PM
Banerjee SubhashisChief Medical OfficerNov 02 '26Sale4.181,1104,641168,738Nov 03 04:04 PM
Aslan FredChief Executive OfficerNov 02 '26Sale4.1862,178259,9721,457,428Nov 03 04:04 PM
Aslan FredChief Executive OfficerOct 06 '26Sale7.2023,463168,8801,519,606Oct 07 04:02 PM
FRED ASLANDirectorOct 06 '26Proposed Sale7.1334,465245,735Oct 06 04:21 PM
Horan ChristopherChief Tech Operations OfficerOct 05 '26Sale6.8410,34070,697312,744Oct 06 04:02 PM
Bush JenniferCOO, CLO, Compliance OfficerOct 05 '26Sale6.848,37057,227366,159Oct 06 04:02 PM
Banerjee SubhashisChief Medical OfficerOct 05 '26Sale6.841,0997,514169,848Oct 06 04:02 PM
Aslan FredChief Executive OfficerOct 05 '26Sale6.8461,696421,8281,543,069Oct 06 04:01 PM
Aslan FredChief Executive OfficerSep 08 '26Sale10.9223,429255,7461,449,765Sep 09 04:02 PM
FRED ASLANDirectorSep 08 '26Proposed Sale11.1923,429262,171Sep 08 04:31 PM
Horan ChristopherChief Tech Operations OfficerSep 03 '26Sale11.1610,366115,638283,084Sep 04 04:04 PM
Bush JenniferCOO, CLO, Compliance OfficerSep 03 '26Sale11.168,39193,606329,529Sep 04 04:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FSMLFranklin Small Cap Enhanced ETFAUM: 150.96M
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 114
  • Why Is Artiva Biotherapeutics Discontinuing AlloNK Development and Cutting 94% of Its Workforce? (InvestorsHub) -30.68%
  • Artiva to quit autoimmune cell therapy work, cut staff after patient deaths (BioPharma Dive)
  • Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths ARTV Stock Heads For Worst Session In Over 18 Months (Stocktwits)
  • Artiva Biotherapeutics stock tumbles after halting drug trial (Investing.com)
  • Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK (GlobeNewswire)
  • Loading…
  • Artiva Biotherapeutics Announces Multiple AlloNK Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 (GlobeNewswire)
  • Artiva Biotherapeutics Highlights Updated AlloNK Data in Sjogren Disease Presented at the 17th International Symposium on Sjogren's Disease (ISSjD 2026) (GlobeNewswire)
  • Artiva Biotherapeutics Announces Oral Presentation of AlloNK Clinical Data at the 17th International Symposium on Sjogren's Disease (GlobeNewswire)
  • Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire)
  • Artiva Biotherapeutics Provides Update on Planned AlloNK Data Disclosures and Development Milestones for the Remainder of 2026 (GlobeNewswire)
  • Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
  • Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.96%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-06-0.630-0.625-0.6630.000.006
2026Q12026-05-08-0.950-0.870-0.9530.000.006
2025Q42026-03-10-0.850-0.844-0.8450.000.006
2025Q32025-11-12-0.880-0.868-0.8790.000.006
2025Q22025-08-06-0.870-0.806-0.8720.000.006
2025Q12025-05-08-0.830-0.711-0.8340.000.006
2024Q42025-03-24-0.660-0.731-0.6630.000.006
2024Q32024-11-12-0.920-0.835-0.7190.000.104
2024Q22024-08-29-22.000-1.380-0.7660.000.103
2024Q12024-05-29-1.420--0.7940.28--
2026Q3---0.547--0.006
2026Q4---0.709--0.006
2027Q1---0.363--0.004
2027Q2---0.303--0.004
2027Q3---0.280--0.004
2027Q4---0.235--0.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-5.810-5.574-2.6910.250.28
2025FY-3.430-3.427-3.4330.000.00
2026FY--2.740--0.00
2027FY--1.552--0.00
2028FY--1.454--0.00
2029FY--0.947--35.09
2030FY--0.134--99.75

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-075000.000.000.00
2026Q3S2026-08-065000.000.000.00
2026Q3S2026-05-085000.000.000.00
2026Q3S2026-03-115000.000.000.00
2026Q3S2025-11-175000.000.000.00
2026Q3S2025-11-124000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00
2026Q3S2025-11-073000.000.000.00
2026Q3S2025-11-063000.000.000.00
2026Q3S2025-11-053000.000.000.00
2026Q3S2025-11-043000.000.000.00

Estimate history

EPS, annual-0.227-1.023-4.085-2.421-1.183-2.691-3.431-2.9955
Period2019202020212022202320242025TTM
EPS, quarterly-0.719-0.663-0.834-0.872-0.879-0.845-0.953-0.634-0.563
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual002.0024.93133.4920.25100
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.58317.58317.58317.58324.28724.29224.59649.265
Period2019202020212022202320242025MRQ
Shares, quarterly24.28724.29224.36324.39424.54524.59624.71748.79249.265
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.2533.494.932.000.000.00
Cost of Goods Sold Incl. D&A2.782.602.432.271.160.250.070.01
Gross Profit-2.78-2.60-2.1831.233.771.75-0.07-0.01
Selling, General and Administrative Excl. Other102.6388.0165.9061.9063.6055.0318.203.12
Research and Development81.4466.9447.9047.9842.8342.1613.771.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-105.41-90.61-68.08-30.67-59.83-53.27-18.27-3.13
Interest Expense---0.000.000.000.200.24
Unusual Expense-0.000.003.600.710.0018.55-0.480.64
Net Income Before Taxes-98.11-83.86-65.37-28.65-58.73-71.83-17.99-3.99
Income Taxes0.000.000.000.070.050.000.000.00
Consolidated Net Income-98.11-83.86-65.37-28.72-58.79-71.83-17.99-3.99
Net Income From Continuing Operations-98.11-83.86-65.37-28.72-58.79-71.83-17.99-3.99
Net Income-98.11-83.86-65.37-28.72-58.79-71.83-17.99-3.99
EPS (Recurring)-1.92-3.43-2.59-1.16-2.42-3.35-1.04-0.20
EPS (Basic, Before Extraordinaries)-3.00-3.43-2.69-1.18-2.42-4.08-1.02-0.23
EPS (Diluted)-3.00-3.43-2.69-1.18-2.42-4.08-1.02-0.23
EBITDA-102.63-88.01-65.65-28.41-58.67-53.02-18.20-3.12
Non-Operating Income (Expense)7.296.756.312.731.090.000.000.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.856.826.985.575.204.310.300.00
Price To Sales Ratio--975.54-----
Gross Margin---868.5393.2376.5287.61--
Operating Margin---27,124.30-91.58-1,213.32-2,660.94--
Net Margin---26,045.02-85.75-1,192.21-3,587.66--
Shares Outstanding49.2724.6024.2924.2917.5817.5817.5817.58
Market Capitalization198.49198.49244.84256.98----

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.750.690.670.670.660.640.630.61
Gross Profit-0.75-0.69-0.67-0.67-0.66-0.64-0.63-0.61
Selling, General and Administrative Excl. Other31.2026.2023.7621.4722.2322.1721.5417.85
Research and Development25.2421.2318.6516.3316.9717.2216.4212.70
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-31.95-26.89-24.43-22.13-22.90-22.81-22.17-18.47
Unusual Expense0.000.00-0.000.000.000.000.000.00
Net Income Before Taxes-28.82-25.00-23.52-20.77-21.53-21.25-20.31-16.09
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-28.82-25.00-23.52-20.77-21.53-21.25-20.31-16.09
Net Income From Continuing Operations-28.82-25.00-23.52-20.77-21.53-21.25-20.31-16.09
Net Income-28.82-25.00-23.52-20.77-21.53-21.25-20.31-16.09
EPS (Recurring)-0.56-0.63-0.95-0.85-0.88-0.87-0.83-0.66
EPS (Basic, Before Extraordinaries)-0.56-0.63-0.95-0.85-0.88-0.87-0.83-0.66
EPS (Diluted)-0.56-0.63-0.95-0.85-0.88-0.87-0.83-0.66
EBITDA-31.20-26.20-23.76-21.47-22.23-22.17-21.54-17.85
Non-Operating Income (Expense)3.131.890.911.361.371.561.862.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.801.861.591.591.631.552.052.18
Price To Sales Ratio-------975.54
Shares Outstanding49.2748.7924.7224.6024.5424.3924.3624.29
Market Capitalization198.49239.75159.18105.3070.1036.7973.09244.84

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments108.01185.4376.97102.53160.9225.441.87
Short Term Receivables0.771.051.760.530.470.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets3.892.161.091.620.900.670.09
Total Current Assets112.67188.6379.82104.67162.2926.111.96
Net Property, Plant & Equipment17.3620.4324.6427.624.082.392.50
Total Investments and Advances0.460.260.260.240.240.000.00
Deferred Tax Assets3.63------
Other Assets0.460.270.390.523.320.730.38
Total Assets134.57209.58105.11133.05169.9329.234.84
Short Term Debt Incl. Current Port. of LT Debt3.063.743.603.490.430.460.21
Accounts Payable0.351.120.611.101.442.150.26
Other Current Liabilities9.677.398.0221.0417.433.150.48
Total Current Liabilities13.0912.2512.2325.6219.305.760.94
Long Term Debt7.8810.6113.3215.961.3144.917.61
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities3.63------
Other Liabilities0.000.0725.1715.7521.760.130.24
Total Liabilities24.6022.9450.7257.3442.3750.808.80
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00216.41216.41216.410.000.00
Common Equity109.97186.64-162.01-140.70-88.86-21.57-3.96
Total Shareholders Equity109.97186.6454.4075.72127.56-21.57-3.96
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity109.97186.6454.4075.72127.56-21.57-3.96
Total Liabilities & Stockholders Equity134.57209.58105.11133.05169.9329.234.84
Book Value Per Share4.477.68-6.67-8.00-5.05-1.23-0.23
Tangible Book Value Per Share4.477.68-6.67-8.00-5.05-1.23-0.23
Full-Time Employees1048977-4325-
Price to Book Ratio0.621.221.28----
Return on Assets-48.74-41.55-24.12-38.81-72.13-105.60-
Return on Equity-56.55-54.24-44.15-57.84-135.53--
Return on Invested Capital-71.16-33.14-42.41-64.12-55.74-77.09-109.17
Quick Ratio8.6115.396.534.088.414.532.08
Current Ratio8.6115.396.534.088.414.532.08

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-98.11-83.86-65.37-28.72-58.79-71.83-17.99-3.99
Depreciation2.782.602.432.271.160.250.070.01
Other Funds (Non Cash)6.754.948.237.3010.6722.860.020.89
Funds from Operations-88.59-76.33-54.71-19.15-46.96-48.72-17.90-3.09
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital4.11-0.42-0.33-28.28-3.8733.414.360.20
Cash from Operating Activities-84.48-76.75-55.03-47.43-50.83-15.30-13.54-2.89
Capital Expenditures-2.12-2.59-0.64-3.26-6.30-1.72-0.28-0.27
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-160.6466.00-119.82-22.720.000.000.000.00
Purchase of Investments-249.45-44.88-176.17-49.520.000.000.000.00
Sale Or Maturity of Investments88.81110.8756.3526.800.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-162.7663.41-120.46-25.98-6.30-1.72-0.28-0.27
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock283.390.37162.3824.39-1.26117.79-0.240.03
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock283.390.37162.3824.39-1.26117.79-0.240.03
Proceedsfrom Stock Options282.720.23162.32-0.01-1.60117.79-0.240.03
Issuance or Reduction of Debt, Net-0.08-0.13-0.150.000.0034.9737.645.00
Change in Long Term Debt-0.08-0.13-0.150.000.0034.9737.645.00
Issuance of Long Term Debt0.000.000.000.000.0034.9737.645.00
Reduction of Long Term Debt-0.08-0.13-0.150.000.000.000.000.00
Net Financing Active Other Cash Flow-0.30-0.230.000.000.000.000.000.00
Other Financing Activities Uses-0.30-0.230.000.000.000.000.000.00
Cash from Financing Activities283.010.01162.2324.39-1.26152.7537.405.03
Net Change in Cash35.77-13.33-13.27-49.01-58.39135.7323.571.87
Free Cash Flow-86.60-79.34-55.67-50.69-57.13-17.03-13.82-3.16
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments319.10349.3986.78108.01122.97142.37
Short Term Receivables1.721.440.600.770.881.03
Inventories0.000.000.000.000.000.00
Other Current Assets5.431.441.363.895.685.67
Total Current Assets326.25352.2888.74112.67129.52149.07
Net Property, Plant & Equipment14.9115.0916.3017.3618.4619.83
Total Investments and Advances0.500.460.460.460.460.46
Deferred Tax Assets---3.63--
Other Assets1.310.810.460.460.420.04
Total Assets342.98368.63105.95134.57148.86169.39
Short Term Debt Incl. Current Port. of LT Debt3.323.303.043.063.173.64
Accounts Payable2.041.392.290.350.851.22
Other Current Liabilities11.059.905.569.677.105.91
Total Current Liabilities16.4114.5810.8813.0911.1210.77
Long Term Debt5.856.557.237.888.529.58
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---3.63--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities22.2621.1318.1124.6019.6420.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity320.72347.5087.85109.97129.22149.04
Total Shareholders Equity320.72347.5087.85109.97129.22149.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity320.72347.5087.85109.97129.22149.04
Total Liabilities & Stockholders Equity342.98368.63105.95134.57148.86169.39
Book Value Per Share6.517.123.554.475.266.11
Tangible Book Value Per Share6.517.123.554.475.266.11
Full-Time Employees134--104106-
Price to Book Ratio0.622.731.440.810.470.22
Return on Assets-39.90-33.76-58.59-48.74-42.29-61.26
Return on Equity-43.61-36.58-67.86-56.55-47.96-86.18
Return on Invested Capital-8.83-7.06-24.73-17.63-15.63-13.40
Quick Ratio19.8824.168.168.6111.6513.84
Current Ratio19.8824.168.168.6111.6513.84

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-28.82-25.00-23.52-20.77-21.53-21.25
Depreciation0.750.690.670.670.660.64
Other Funds (Non Cash)2.311.751.391.301.271.04
Funds from Operations-25.76-22.56-21.46-18.81-19.59-19.57
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.692.210.514.080.39-3.41
Cash from Operating Activities-28.45-20.36-20.95-14.73-19.20-22.98
Capital Expenditures-1.04-0.41-0.24-0.42-0.60-1.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-210.6618.0015.5616.4616.8822.18
Purchase of Investments-235.470.00-6.44-7.54-12.74-6.07
Sale Or Maturity of Investments24.8118.0022.0024.0029.6228.25
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-211.7017.5915.3216.0416.2821.12
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.03283.280.130.000.100.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.03283.280.130.000.100.00
Proceedsfrom Stock Options-0.48283.080.130.000.100.00
Issuance or Reduction of Debt, Net0.00-0.01-0.03-0.03-0.03-0.03
Change in Long Term Debt0.00-0.01-0.03-0.03-0.03-0.03
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.01-0.03-0.03-0.03-0.03
Net Financing Active Other Cash Flow0.000.00-0.21-0.09-0.10-0.04
Other Financing Activities Uses0.000.00-0.21-0.09-0.10-0.04
Cash from Financing Activities-0.03283.27-0.11-0.12-0.04-0.07
Net Change in Cash-240.18280.50-5.751.19-2.96-1.93
Free Cash Flow-29.49-20.77-21.19-15.15-19.80-24.04

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 251.00K
United States2024: 251.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.58%3.0M17.8M624.84K
2026-10-1515.36%2.7M17.8M404.56K
2026-09-306.90%2.3M33.3M403.70K
2026-09-156.22%2.1M33.2M417.41K
2026-08-315.25%1.8M35.0M477.38K
2026-08-145.99%2.1M35.0M519.78K
2026-07-315.25%1.9M36.6M598.30K
2026-07-158.13%1.7M21.2M612.17K
2026-06-304.40%1.3M30.5M574.53K
2026-06-156.96%1.1M15.5M470.64K
2026-05-296.62%1.0M15.5M400.08K
2026-05-152.60%0.5M18.5M345.96K
2026-04-301.89%0.2M12.2M229.42K
2026-04-151.22%0.1M12.2M187.24K
2026-03-311.20%0.1M12.4M183.31K
2026-03-131.19%0.1M12.4M1.05M
2026-02-271.21%0.1M12.3M1.01M
2026-02-131.54%0.2M12.3M1.01M
2026-01-301.74%0.2M11.7M1.03M
2026-01-152.43%0.3M11.7M3.05M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.900.000.0000.000.000.907-0.0170.001
call5.000.000.050.051.0982,2280.000.144-0.0090.002
call7.500.000.100.052.3525970.000.081-0.0120.001
call10.000.000.050.053.1201,3760.000.066-0.0140.001
call12.500.000.050.203.67416.000.000.059-0.0150.001
call15.000.000.051.364.10751.000.000.054-0.0150.001
call17.500.000.051.004.46170.000.000.051-0.0160.001
call20.000.000.050.054.75912.000.000.049-0.0160.001
call22.500.003.600.005.1860.000.000.047-0.0180.001
put2.500.000.100.052.24010.000.00-0.066-0.0100.001
put5.000.001.350.852.8542720.00-0.855-0.0090.001
put7.501.005.800.0012.7650.000.00-0.919-0.0120.001
put10.003.508.300.0013.8350.000.00-0.934-0.0140.001
put12.506.0010.900.0014.9540.000.00-0.941-0.0140.001
put15.008.5013.400.0015.5260.000.00-0.946-0.0150.001
put17.5011.0015.900.0015.9840.000.00-0.949-0.0150.001
put20.0013.5018.400.0016.3700.000.00-0.951-0.0150.001
put22.5016.0020.900.0016.7050.000.00-0.953-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-K/A2026-10-22SEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-278-KCurrent report2026-10-22SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-118-KCurrent report2026-09-08SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100343.48K4
2026-1000726.15K5
2026-09001.17M5
2026-0800103.88K2
2026-075.08M1000
2026-0612.54M800
2026-0591.50M3477.77K5
2026-040000
2026-030000
2026-020000
2026-010000
2025-120019.12K1
2025-110021.52K1

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.72.65%
VIKING GLOBAL INVESTORS LP10.54%
Blackstone Inc.9.72%
5AM Venture Management, LLC9.52%
Venrock Adviser, LLC8.27%
FRANKLIN RESOURCES INC8.08%
Caligan Partners LP7.02%
VANGUARD CAPITAL MANAGEMENT LLC3.97%
Samsara BioCapital, LLC3.86%
Blue Owl Capital Holdings LP3.54%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.83%
Franklin Biotechnology Discovery Fund1.12%
VANGUARD EXTENDED MARKET INDEX FUND1.09%
Franklin Small Cap Growth Fund0.94%
iShares Russell 2000 ETF0.57%
Simplify Propel Opportunities ETF0.41%
Fidelity Extended Market Index Fund0.24%
VANGUARD U.S. MOMENTUM FACTOR ETF0.21%
Ultra-Small Company Fund0.20%
Ultra-Small Company Market Fund0.14%

OakChart. ARTV. Cached 15 minutes.